CLINEXEL at ESDR 2026 | Advancing Chronic Wound Clinical Research

Dr. Deepa Arora, MD, CEO of CLINEXEL, presented her scientific poster at the 55th Annual Meeting of the European Society for Dermatological Research (ESDR 2026) in Heidelberg, Germany.

Her poster, “Optimizing Endpoint Selection in Chronic Wound Clinical Trials: Balancing Regulatory Expectations, Clinical Relevance, and Operational Feasibility in India,” explores key considerations in designing robust clinical trials for chronic wound therapies.

The work highlights the importance of selecting clinically meaningful, patient-centered, and regulatorily acceptable endpoints, while also addressing the operational realities of conducting global studies.

As the development of advanced wound therapies, medical devices, regenerative medicines, and biologics continues to evolve, thoughtful endpoint selection is essential for generating high-quality clinical evidence that supports regulatory decision-making and ultimately contributes to improved patient care.

At CLINEXEL, we remain committed to supporting sponsors with scientifically rigorous and operationally efficient clinical development programs.

We thank the ESDR community for providing an outstanding platform for scientific exchange and collaboration. It was a privilege to engage with researchers, clinicians, and industry experts from around the world.

#ESDR2026 #ESDR #DermatologyResearch #ChronicWounds #ChronicWoundClinicalTrials #ClinicalResearch #ClinicalTrials #ClinicalDevelopment #MedicalDevices #RegenerativeMedicine #Biologics #DrugDevelopment #RegulatoryAffairs #ClinicalResearchOrganization #CRO #Clinexel